Baxter CEO is former Abbott exec
Executive Summary
Former Abbott president Robert Parkinson, 53, becomes Baxter chairman and CEO on April 26. Parkinson's primary task will be to restore investor confidence and earnings visibility at Baxter after several quarters of missed earnings targets led to the resignation of Harry Kraemer as the company's top executive (1"The Pink Sheet" Feb. 2, 2004, In Brief). Parkinson has been dean of Loyola University Chicago's business school since 2002 and was Abbott Labs president and chief operating officer from 1999 to 2002...
You may also be interested in...
Baxter CEO steps down
Baxter CEO Harry Kraemer plans to leave the company as soon as a successor is found. Baxter has been dogged by problems related to its plasma business and the adoption rate of the anti-hemophilic factor VIIIAdvate. Former Johnson & Johnson President James Lenehan is the most widely speculated candidate; other potential contenders are Integra LifeSciences CEO Stuart Essig and Garrett Capital Advisors Managing Partner Jim Connelly. Baxter has hired Heidrick & Struggles to head up the search...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.